A live biotherapeutic product is a drug made of living microorganisms, usually bacteria, dosed to colonize or rebalance a patient's gut microbiome. Unlike a small molecule or even most biologics, the active ingredient is not a stable molecule at all, it is a population of living cells that has to survive shipping, storage, and dosing while remaining alive and able to multiply once inside the patient. That single fact, the drug is alive, sets every packaging and handling decision that follows.
Most live biotherapeutic products ship frozen, often below -20°C, because freezing is the most reliable way to hold a bacterial population dormant without it dying off during transit. A smaller number of formulations are stabilized enough to tolerate ordinary refrigeration, but freezing remains the default for anything that has not been specifically engineered and tested for a warmer shelf life.
Viability as the quality attribute
A conventional drug's potency is chemical and can be measured directly from a sample's composition. A live biotherapeutic's potency is biological: the number of living, viable organisms per dose, usually reported as colony-forming units. That number only moves one direction over time and under stress, down, and it does not recover. A shipment that arrives at the correct temperature has not necessarily arrived with enough live organisms to work, because viability loss can happen gradually across many small temperature excursions rather than one obvious failure.
Manufacturers set a release specification for the minimum viable count a dose must carry, similar in concept to a potency assay for a conventional biologic, but that number keeps falling after release, through shipping, storage, and handling, in a way a chemical potency reading does not. A batch that cleared release testing comfortably can still arrive at a hospital pharmacy below the threshold needed to work, and nothing about the shipment's paperwork or appearance will show that on its own.
Loss that does not show on inspection
This is the trap specific to this product class. A vial of dead bacteria looks identical to a vial of live bacteria, same color, same volume, same label. There is no visual or quick chemical test that confirms a dose is still potent, only a colony-forming unit assay run in a lab, which takes days and cannot be done at the bedside before dosing. Every other cold chain product in this space at least offers some correlation between visible condition and quality; a live biotherapeutic offers none, which is why temperature monitoring and time-out-of-refrigeration limits are treated as the real proxy for potency rather than a compliance formality.
Frozen and refrigerated formulations side by side
A manufacturer's live biotherapeutic portfolio can include one product validated frozen and another, stabilized differently, validated for a 2-8°C refrigerated band like a conventional biologic. The two lanes are not interchangeable. An organism validated frozen and shipped instead through a refrigerated-only chain, or the reverse, has not been tested under those conditions, and its viability loss there is unknown rather than simply unmeasured.
Limits of freezing as a fix
Freezing solves the storage stability problem but creates a new one at the point of use: the product has to be thawed correctly before dosing, and thawing itself stresses the organisms through the same ice-formation mechanisms that damage other frozen biological material. A clinic that thaws too quickly, refreezes a partially used dose, or holds a thawed dose too long before administration can destroy viability that survived the entire shipping chain intact. Freezing is not a universal answer either: some organisms do not survive a freeze-thaw cycle well regardless of protocol, which is why development work on stabilized, refrigeration-tolerant formulations continues rather than defaulting every candidate to a frozen presentation.
Manufacturers and the regulators who classify them
Live biotherapeutic products sit in a regulatory category of their own, distinct from conventional drugs and from most other biologics, and manufacturers, contract fill-finish sites, and hospital or specialty pharmacies handling the product all follow cold chain protocols specific to a living organism rather than a chemical compound. Clinical development work on new organisms runs through the same trial supply logistics used for other investigational biologics, with the added constraint that a viability assay, not just a visual or chemical check, has to confirm every batch before it can be dosed to a trial participant.
Hospital pharmacies handling these products face a training gap most staff have not met with conventional drugs: a vial that looks, smells, and handles exactly like any other frozen product but degrades invisibly if it sits out of the freezer even briefly longer than its validated limit. Pharmacy staff trained on visual inspection for damaged packaging or discoloration have nothing comparable to check here, which pushes the whole quality burden onto the temperature log and the handling procedure instead.